24 results
Thumbnail

D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community

Thumbnail

D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results

Thumbnail

D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals

Thumbnail

D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach

Thumbnail

D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children

Thumbnail

D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels

Thumbnail

D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results

Thumbnail

D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency

Thumbnail

- D1.323 - Clinical Experience with Lanadelumab for Hereditary Angioedema in Kazakhstan

Thumbnail

D3.317 - Moderate-to-severe infections and initial SELENA-SLEDAI correlate with the incidence of flares in patients with Systemic Lupus Erythematosus

Thumbnail

D3.322 - Acquired chronic granulomatous disease secondary to myelodysplastic disorder

Thumbnail

D3.324 - Mastoiditis as complication of Hyper IgM syndrome

Thumbnail

D3.326 - A RARE COEXISTENCE: CARD9 DEFICIENCY AND IgG4-RELATED DISEASE IN A PEDIATRIC PATIENT

Thumbnail

D3.327 - Use of C1 Inhibitor Subcutaneously in the United Kingdom

Thumbnail

D3.328 - Relapsing COVID-19 pneumonia and Helicobacter cineadi cellulitis in a patient with X-linked agammaglobulinemia

Thumbnail

D3.332 - Determination of Reference Intervals for IgG, IgA, and IgM Levels by Age in Healthy Adults

Thumbnail

D3.389 - Deep Learning-Based Real-Time Identification of Wheezing in Lung Sounds: Applications in Disease Prediction and Early Intervention

Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Thumbnail

D3.391 - Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Thumbnail

D3.392 - What information and education is crucial for people with food allergies?